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combined. Results: Using pneumococcal vaccine only enables to achieve the 
targeted 15% reduction in cases, hospital occupancy or deaths at annual cov-
erage of respectively 76.9%, 81.0%, 57.1%, and at the lowest annual vaccination 
budget of respectively € 26, € 27 and € 19 million. If meningococcal type B vaccine 
were prioritized in a UMV program, pneumococcal vaccine should still be added 
to achieve the public health objective. In such scenario, the annual vaccination 
budget would amount to € 57, € 59 and € 48 million, at the maximum achievable 
coverage of 60% for meningococcal vaccine and pneumococcal coverage of 76.8%, 
80.8% and 47.9%. ConClusions: Pneumococcal vaccine on its own can achieve 
the targeted 15% reduction in disease burden at the lowest vaccination budget. 
Vaccination against pneumococcal disease should therefore be prioritized in a 
UMV program in Poland.
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objeCtives: Varicella is a common childhood disease caused by varicella-zoster 
virus (VZV). Annually it affects around 651,000 individuals with 42% consulting 
general practitioners and 0.5% being hospitalized with recent trend of increase 
in the United Kingdom (UK). This poses significant public health concern due to 
high infection rates and associated economic burden. In countries with routine 
varicella vaccination significant reduction in varicella burden was observed. This 
study assesses the cost-effectiveness of introducing varicella vaccination as an 
addition to the current childhood immunization schedule of mumps, measles and 
rubella (MMR) vaccine in the UK. Methods: An age-structured dynamic transmis-
sion model was fitted to VZV seroprevalence in the non-vaccinated population 
in the UK. The model simulated the evolution of varicella and herpes zoster with 
and without vaccination with a lifetime horizon. The vaccination strategy con-
sidered coverage and age at dose 1 (90%;1year) and 2 (80%;3years), and catch up 
at 12 years with 20% coverage. Costs and effects are discounted at 3.5%. Results: 
The Incremental Cost Effectiveness Ratio at 5 and 15 years post introduction of 
vaccination with high coverage were £6,012(95%CI:-370;13,221)/Quality-Adjusted 
Life-Year (QALY) and £6,431(95%CI:337;13,188)/QALY, respectively. There were 
significant savings for outpatient and hospitalization costs: £22,274,734 and 
£5,178,472 by year 5; £82,954,153 and £17,470,473 by year 15, respectively. Varicella 
cases avoided following 5 and 15 years post implementation of vaccination were 
399,604 (57.7%) and 655,232 (94.8%), respectively. ConClusions: Implementing 
varicella vaccination in the UK will reduce the disease burden both in terms of 
varicella cases and associated costs, and is likely to be cost-effective. However, 
high vaccination coverage is required to achieve high impact of vaccination. 
Depending on the evolution of the UK vaccination schedule, vaccination with 
either monovalent varicella vaccine or combination MMR+Varicella vaccine 
could be a suitable option for implementation of varicella vaccination as part of 
a national immunization program.
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objeCtives: Estonia is now considering adding a pneumococcal conjugate vac-
cine (PCV) in its national immunization program to help reduce the burden of 
invasive pneumococcal diseases, pneumonia and acute otitis media (AOM). In 
this cost-effectiveness analysis (CEA), we estimate the vaccine price under which 
vaccinating with the pneumococcal non-typeable Haemophilus influenzae protein 
D conjugate vaccine (PHiD-CV) is considered cost-effective compared to no vac-
cination. Methods: A static cohort model (Knerer et al. 2012) has been adapted 
for Estonia using local serotype distribution, disease incidence and direct medical 
costs. Vaccine efficacy assumptions come from large PCV randomized controlled 
trials. Base case parameters have been validated by an expert panel and other 
scenarios were explored in extensive sensitivity analyses. CEA perspective is a 
modified healthcare payer (only including parents’ sick leave costs). The cohort 
is vaccinated at 2, 4 and 12 months with 95% coverage and followed over a life-
time (5% annual discount). Results: Under base case assumptions, vaccinating a 
cohort of 14,021 infants in Estonia with PHiD-CV would prevent 3927 AOM-related 
outpatient visits, 248 myringotomies, 93 cases of pneumonia, 8 cases of meningitis 
and 3 deaths over the cohort’s lifetime. Total effectiveness results translate into 
533 quality-adjusted life years (QALYs) gained and € 706,242 saved in treatment 
costs (undiscounted). With a Gross Domestic Product (GDP) per capita of € 14,860 
in Estonia (2014), the program would then be considered highly cost-effective 
(discounted incremental cost-effectiveness ratio (ICER) < 1 GDP/capita) if the vac-
cine price is below € 28.69/dose (€ 51.38 and € 74.08/dose for 2 and 3 GDP/capita, 
respectively). Reducing base case net herd protection by half, discounting at 3% 
and accounting only for direct medical costs would result in highly cost-effective 
thresholds of € 21.47, € 56.20 and € 25.63/dose, respectively. ConClusions: Our 
model predicts that PCV vaccination would be highly cost-effective under € 28.69/
dose and cost-effective until € 74.08/dose in Estonia.
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objeCtives: Herpes zoster (HZ), caused by reactivation of varicella zoster virus, is 
characterized by dermatome-based rash and severe pain. Post-herpetic neuralgia 
may occur following HZ. The risk of HZ increases with older age and reduced 
immunity. HZ vaccine has been first approved for adults aged 60 years and 
four, cost-effectiveness in two, cost benefit in one, cost-utility in one and general 
cost in one. All studies demonstrated satisfactory economic results comparing OPAT 
to inpatient care however fragile methodology was observed in the majority of 
study. ConClusions: in this review OPAT was a strategy that saved resources with 
favorable outcome in terms of related infection and complications.
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objeCtives: HCV infection is a leading cause of chronic liver disease with long-
term complications - extensive fibrosis, cirrhosis and hepatocellular carcinoma. The 
objective of this study is to perform analysis of the cost of therapy of patients with 
chronic HCV - related cirrhosis in Bulgaria. Methods: It is a combined prospective 
and retrospective, real life observational study of 301 patients with chronic HCV 
infection and cirrhosis monitored in the University Hospital “Queen Joanna-ISUL” 
for 3-year period (2012-2014). Data on demographic, clinical characteristics and 
healthcare resources utilization (hospitalizations, highly-specialized interven-
tions, pharmacotherapy) was collected. Micro-costing approach was applied to 
evaluate the total medical costs. The points of view are that of the National Health 
Insurance Fund (NHIF), hospital and the patients. Collected cost data are from the 
NHIF and hospitals tariffs, patients, and from the positive dug list for medicines 
prices. Statistical processing was through descriptive statistics and Chi-squared 
test. Results: 76% of patients were male. 93% were diagnosed in grade A and B 
according to Child-Pugh classification. 97% reported complications, and almost all 
developed esophageal varices. 847 hospitalizations were recorded for 3 years period 
with average length of stay 17 days. The mortality rate of 7% was extremely high. 
The total direct medical costs for the observed cohort of patients for 3-year period 
accounted for 1,2 million BGN (0.6 million EURO) and average cost per patient per 
year is 1343 BGN (671 Euro). The proportion of cost paid by the NHIF is 2/3 to 1/3 
for the hospital and the patients. A statistically significant correlation between 
the age, follow-up, number of hospitalizations and the Child-Pugh stage was 
found. ConClusions: HCV-related cirrhosis is resource demanding and implicit 
high direct medical costs as it is related with lots of hospitalizations and leads to 
complications acquiring additional treatment.
PIN42
the cost of treatINg recurreNt clostrIdIum dIffIcIle INfectIoN IN 
PatIeNts atteNdINg INfectIous dIsease clINIcs at four hosPItals IN 
swedeN
Jensen AV1, Fraenkel CJ2, Åkesson P2, Noren T3, Rundlöf Nygren P4, Lennebratt D4,  
Hagberg L5
1MSD, Stockholm, Sweden, 2Skåne University Hospital, Lund, Sweden, 3Örebro University 
Hospital, Örebro, Sweden, 4Uppsala University Hospital, Uppsala, Sweden, 5Sahlgrenska 
University Hospital, Gothenburg, Sweden
objeCtives: The aim of this study is to investigate the cost of treating recurrent 
Clostridium difficile infection in patients attending infectious disease clinics at 4 
hospitals in Sweden. Methods: Following approval by the Central Ethical Review 
Board in Stockholm patient records of 120 patients were used to record the resources 
used to treat the latest recurrent infection. Recurrence was defined as a new toxin-
positive Clostridium difficile infection within 12 weeks of the previous Clostridium 
difficile infection. The sample included 47 patients not hospitalized and 73 hos-
pitalized patients. All resources used were itemized and a point estimate of the 
associated costs calculated using the average of two or more pricelists from county 
councils in Sweden. Results: This study shows that the treatment costs at the four 
participating infectious disease clinics in Sweden for treating a single event of recur-
rent Clostridium difficile infection ranged from SEK 921 to SEK 278323. Median cost 
for non-hospitalized patients was SEK 5397 and for hospitalized patients SEK 68078. 
We found that the 10% of the patients with the highest resource use accounted 
for MSEK 2,38, or nearly 40% of the accumulated resource use of MSEK 6,25 used 
to treat the 120 studied patients. ConClusions: Significant costs are associated 
with treatment of recurrent Clostridium difficile infections, especially when hos-
pitalization is needed. Minimizing the need for hospitalization during treatment 
is the single most important objective when minimizing the economic burden of 
recurrent Clostridium difficile infection.
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objeCtives: Considering the burden of meningococcal and pneumococcal disease 
in 0-5 years old children in Poland, we aimed at determining which vaccine(s) to 
prioritize for a Universal Mass Vaccination (UMV) program to reduce the burden 
by 15% at the lowest annual budget. Methods: A Pediatric Expert Group on the 
Immunization Program in Poland defined pneumococcal vaccines as a priority 
based on epidemiological data (high frequency with growing antibiotic resistance) 
but the need for prevention against meningococcal disease was also highlighted. 
A vaccine portfolio management model was adapted to the Polish situation, con-
sidering pneumococcal and meningococcal (type B and C) vaccines. This opti-
mization model determines the optimal combination of vaccines to achieve a 
targeted public health objective at the lowest annual vaccination budget. Disease 
incidences, treatment pathways, vaccine efficacies, and maximal achievable UMV 
coverages were derived from published sources and expert opinion. The public 
health goal was to reach a 15% reduction over 5 years in disease cases, hospital 
occupancy or deaths related to both pneumococcal and meningococcal disease 
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objeCtives: In adults, the incidence of S. pneumoniaeinfections and the related 
mortality increase with age and co-morbidities. The Belgian Superior Health Council 
recommends use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults 
with elevated risk of pneumococcal diseases. PCV13 has recently proven effica-
cious in preventing pneumococcal pneumonia and invasive pneumococcal dis-
ease (IPD) in the elderly. We investigated the cost-effectiveness of vaccinating the 
65-84 y. old cohort (n= 862,188) that suffer from co-morbidities or immunosuppres-
sion Methods: A cohort model with a Markov-type process was developed to 
project the lifetime risks and related costs of IPD and nonbacteremic pneumococcal 
pneumonia. Input data came from various sources (literature, existing databases, 
and observational studies) and were reviewed by a panel of Belgian experts. PCV13 
effectiveness was derived from the recently published CAPiTA clinical trial results 
for the first 5 years. Protection gradually declined thereafter to zero by year 16. 
Belgian National Health perspective was taken with costs and quality-adjusted life 
years (QALYs), discounted annually by 3% and 1.5%, respectively. Sensitivity analyses 
on key parameters were performed in order to test the robustness of model find-
ings. Results: 58% vaccination coverage with PCV13 in 65-84 year olds suffering 
from co-morbidities or immunosuppression is expected to prevent 6,798 cases of 
pneumococcal disease, and 911 disease-related deaths over lifetime compared to 
no vaccination. PCV13 vaccination cost was fully offset by reduction in disease-
related costs (€ 61 million), and thus was overall cost-saving. In the one-way sensi-
tivity analysis, results were most sensitive to PCV13 price and parameters related 
to inpatient pneumonia. In probabilistic sensitivity analysis, PCV13 dominated the 
no vaccination strategy in 97% of the simulations. ConClusions: PCV13 vaccina-
tion of the 65-84 year-old cohort in Belgium would prevent a substantial number 
of cases and deaths from severe pneumococcal disease and be cost-saving from a 
healthcare perpective .
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objeCtives: Herpes Zoster (HZ) and its most common complication, Post-Herpetic 
Neuralgia (PHN), are painful and debilitating conditions with an important burden 
for patients and society. A live-attenuated one-dose vaccine was licensed in 2006 
for the prevention of both HZ and PHN in adults 50+ years old and is currently 
recommended and part of vaccination calendars in several countries. The objec-
tive of this study was to assess the cost-effectiveness of zoster vaccination for the 
50+ population in Portugal. Methods: An existing European Markov cohort model 
was adapted to the Portuguese healthcare setting. Health states considered are 
healthy, HZ, PHN, healthy post-HZ and death. HZ and PHN states are further split 
by pain severity (mild, moderate or severe). According to local guidelines, the cost-
effectiveness outcomes were assessed from the societal perspective for a public 
reimbursement at 37%. Analysis comparing a HZ vaccination for adults aged ≥ 50 
years with no vaccination was done. Input data were obtained from Portuguese 
sources whenever available. Results: The strategy of vaccinating adults 50+ years 
old showed an incremental cost-effectiveness ratio of 19.625€ per quality adjusted 
life year (QALY) gained from a societal perspective. The analysis showed cost-effec-
tiveness improvement with age with an ICER in the 65+ population of 15.517€ /QALY 
from the societal perspective. The probabilistic sensitivity analyses showed that 
for high levels of certainty (95%) the ICER does not exceed 25.000€ /QALY from the 
societal perspective. ConClusions: Considering the generally acceptable thresh-
old, the present cost-effectiveness analysis demonstrates that HZ vaccination for 
adults 50+ years old in Portugal is a cost-effective strategy. Vaccine reimbursement 
would provide substantial health, social and economic benefits in the Portuguese 
health care context.
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objeCtives: To estimate the cost-effectiveness of three candins (anidulafungin, 
caspofungin, and micafungin) and generic fluconazole in the treatment of non-neu-
tropenic adult patients with candidemia and/or invasive candidiasis (IC) in intensive 
care units (ICU) in Spain. Methods: A decision tree model was performed. The 
success (clinical and microbiological response) and safety (hepatic and renal adverse 
effects) of first-line treatments were obtained from meta-analyses and systematic 
reviews of clinical trials. In the case of failure, a second-line treatment (liposomal 
amphotericin B after the candins, or one of the candins after fluconazole) was 
administered. The duration of the treatments (14 days total) was established by 
IDSA guidelines. The cost of the medications and renal toxicity were considered. 
Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations 
were carried out. Results: The total cost of the treatment of candidemia and/or 
invasive candidiasis with anidulafungin, caspofungin, micafungin, and flucona-
zole was € 5483, € 5968, € 6231, and € 2088, respectively. Anidulafungin was the 
dominant treatment (more effective, less expensive) compared to micafungin and 
above, and recently approved for 50 years and above. The aim of present study 
was to evaluate the cost-effectiveness of implementing HZ vaccination program 
for adults at age 50 years versus 60 years in Hong Kong from the perspective of 
society. Methods: A Markov model was designed to compare the clinical and 
economic outcomes of a hypothetical cohort of 50-year-old adults with (1) no 
HZ vaccination, (2) vaccination at 50-year-old, and (3) vaccination at 60-year-old. 
Model inputs were retrieved from literature. HZ-associated total costs (direct and 
indirect costs) and quality-adjusted life years (QALYs) loss were outcome measures 
of the model. Sensitivity analyses were conducted to examine the robustness of 
model results. Results: In base-case analysis, the two vaccination strategies were 
more costly with less QALY loss than no vaccination. Comparing to no vaccination, 
incremental cost-effectiveness ratio (ICER) of vaccinating at 50 and 60 years old 
were HKD175,397 per QALY saved and HKD190,174 per QALY saved, respectively 
(USD1= HKD7.8). All-cause death rate and prevalence of HZ were two potential 
influential factors on the base-case results. In 10,000 Monte Carlo simulations, the 
probability of HZ vaccination at 50-year-old to be the preferred option was 98.2% 
of time, using the gross domestic product per capita in Hong Kong (HKD297,360) 
as threshold of willingness-to-pay. ConClusions: HZ vaccination for adults aged 
50-year-old in Hong Kong seems to be the preferred option when compared to 
vaccination at 60-year-old and no vaccination.
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objeCtives: In Germany, vaccination of infants with a 13-valent pneumococcal 
conjugate vaccine (PCV13) and of individuals > = 60 years with a 23-valent pneumo-
coccal polysaccharide vaccine (PPSV23) is recommended to prevent pneumococcal 
diseases. Recently, PCV13 was also approved for individuals > = 50 years. The study 
assesses the cost-effectiveness of four vaccination strategies targeting adults > = 60 
years in Germany: no vaccination, vaccination with PCV13 only, vaccination with 
PPSV23 only, and sequential-vaccination (PCV13+PPSV23). Methods: A suscepti-
ble-infected-susceptible type model based on ordinary differential equations was 
developed to capture the dynamic transmission of pneumococcal carriage. The 
model compartments were further stratified by age- and pneumococcal serotype-
groups. Model parameters were either retrieved from the literature or obtained 
by fitting against local incidence data. The epidemiological impact of childhood 
PCV13-vaccination (herd and serotype replacement effects) on incidence and 
serotype mix among adults as well as components of the four adult vaccination 
strategies was implemented in the model. A health-economic model was built to 
compute the incremental cost-effectiveness ratios (ICER) per QALY using German 
cost data. The robustness of the model results was assessed through sensitivity 
analyses regarding uncertain input data. Results: In the base case, the ICER of 
PPSV23 vs. no vaccination was € 24,085/QALY. Immunization with PCV13 alone was 
dominated by PPSV23-vaccination. Sequential vaccination vs. PPSV23 vaccina-
tion resulted in € 400,528/QALY. Main reason for the higher ICERs of the latter two 
strategies was a sharp decline in PCV13-serotypes prevalence among adults as 
an indirect result of infant PCV13-vaccination. Sensitivity analyses identified the 
effectiveness of PPSV23 against non-invasive pneumococcal pneumonia to have a 
substantial impact on the model results and be a major source of uncertainty due 
to the heterogeneity in reported effectiveness/efficacy data. ConClusions: From 
a health economic perspective, PPSV23 would be the preferred vaccine to be used 
for the prevention of pneumococcal disease in adults in Germany.
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objeCtives: Assess the cost-effectiveness of the reinstatement (stopped in 2003) of 
an 18-month booster dose of diphtheria, tetanus and acellular pertussis (DTPa-18-
month) vaccine on the National Immunisation Program (NIP) in Australia, focusing 
on pertussis prevention. Methods: The economic evaluation was conducted in 
two stages: (a) the annual epidemiological effect of the vaccination was assessed at 
steady state with an age-stratified, compartmental dynamic population model cali-
brated on Australian pertussis sero-incidence data, allowing estimation of under-
reporting of pertussis using published notification rates, (b) evaluation of total costs 
and quality adjusted life years (QALYs) associated with pertussis cases using a static 
decision tree model. Two scenarios were compared: the current DTP vaccination 
schedule (2, 4, 6 months; 4 years; 12 years) with and without DTPa-18-month (cov-
erage 83%; effectiveness 88%). Direct medical costs, from a payer perspective, and 
pertussis related QALYs lost were generated via data retrieved from the literature 
and Australian tariffs. A discount rate of 5% was applied to costs and outcomes, and 
a 100-year time horizon used. The pertussis cases, hospitalization, costs and QALYs 
were estimated and compared between strategies. One-way sensitivity analyses 
were conducted on the incremental cost-effectiveness ratio (ICER) by varying key 
parameters. Results: DTPa-18-month was projected to prevent 1.3 million symp-
tomatic pertussis cases; 2,762 hospitalizations; gaining 22,430 QALYs at an increased 
cost of $70,667,758. The predicted ICERs were; $54 per symptomatic pertussis case 
avoided, $3,151 per QALY gained, and $25,590 per hospitalization avoided. Most 
benefit was incurred by the target population, aged < 4 years. Infectiousness level, 
pertussis incidence rate, vaccine cost, administration fee and utility loss for unre-
ported cases were predicted to have the largest effect on the ICER. ConClusions: 
Reintroduction of DTPa-18-month in the Australian NIP was demonstrated to be a 
cost-effective strategy.
